You are here

Article Text

Article menu
Download PDFPDF
Chronic obstructive pulmonary disease
Cardiovascular events in patients with COPD: TORCH Study results
  1. Peter M A Calverley1,
  2. Julie A Anderson2,
  3. Bartolome Celli3,
  4. Gary T Ferguson4,
  5. Christine Jenkins5,
  6. Paul W Jones6,
  7. Courtney Crim7,
  8. Lisa R Willits2,
  9. Julie C Yates7,
  10. Jørgen Vestbo8 on behalf of the TORCH Investigators
  1. 1University Hospital Aintree, Liverpool, UK
  2. 2GlaxoSmithKline, Middlesex, UK
  3. 3Caritas-St Elizabeth's Medical Center, Brighton, Massachusetts, USA
  4. 4Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USA
  5. 5Woolcock Institute of Medical Research, NSW, Australia
  6. 6University of London, London, UK
  7. 7GlaxoSmithKline, Research Triangle Park, North Carolina, USA
  8. 8Hvidovre Hospital, Hvidovre, Denmark and Wythenshawe Hospital, Manchester, UK
  1. Correspondence to Professor P M A Calverley, Department of Medicine, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK; pmacal{at}liverpool.ac.uk

Abstract

Background Previous studies have suggested that long-term use of β agonists to treat chronic obstructive pulmonary disease (COPD) may increase the risk of cardiovascular adverse events. In this post hoc analysis, data from the TOwards a Revolution in COPD Health (TORCH) study were used to investigate whether use of the long-acting β2 agonist salmeterol over 3 years increased the risk of cardiovascular adverse events in patients with moderate to severe COPD.

Methods TORCH was a randomised, double-blind, placebo controlled study conducted at 444 centres in 42 countries. Patients (n=6184; safety population) received twice daily combined salmeterol 50 μg plus fluticasone propionate 500 μg (SFC), either component alone, or placebo. Adverse events were recorded every 12 weeks for 3 years.

Results The probability of having a cardiovascular adverse event by 3 years was 24.2% for placebo, 22.7% for salmeterol, 24.3% for fluticasone propionate and 20.8% for SFC. Although a history of myocardial infarction doubled the probability of cardiovascular adverse events, the event rates remained similar across treatment groups.

Conclusion Post hoc analysis of the 3-year TORCH dataset showed that salmeterol alone or in combination (SFC) did not increase the risk of cardiovascular events in patients with moderate to severe COPD.

  • COPD Pharmacology

https://doi.org/10.1136/thx.2010.136077

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding This work was supported by GlaxoSmithKline.

    • Competing interests PMAC has received consulting fees from AstraZeneca, GlaxoSmithKline, Nycomed and Pfizer; speaking fees from GlaxoSmithKline and Nycomed; and grant support from Boehringer-Ingelheim and GlaxoSmithKline. JAA, CC, LRW and JCY are employed by and hold stock in GlaxoSmithKline. BC has received consulting fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; speaking fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; and grant support from Boehringer-Ingelheim and GlaxoSmithKline. GTF has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Schering Plough; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Altana, Boehringer-Ingelheim, Emphasys Medical Inc, Forrest, GlaxoSmithKline, Mannkind Corporation and Novartis. CJ has received consulting fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; speaking fees from Altana, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline and Novartis; and grant support from GlaxoSmithKline. PWJ has received consulting fees from AstraZeneca, GlaxoSmithKline, Novartis and Roche; speaking fees from AstraZeneca and GlaxoSmithKline; and grant support from Boehringer-Ingelheim and GlaxoSmithKline. JV has received consulting fees from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Hoffman-LaRoche and Nycomed; speaking fees from AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; and grant support from GlaxoSmithKline.

    • Ethics approval The study was approved by local ethics review committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave written informed consent.

    • Provenance and peer review Not commissioned; externally peer reviewed.